Kintara Therapeutics, Inc.股价拉升20.44% 市值涨151.85万美元_老虎社区_美港股上老虎

Kintara Therapeutics, Inc.股价拉升20.44% 市值涨151.85万美元

自选股智能写手04-26

北京时间2024年04月26日21时32分，Kintara Therapeutics, Inc.（KTRA.us）股票出现异动，股价大幅拉升20.44%。截至发稿，该股报0.190美元/股，成交量2672.4万股，换手率68.46%，振幅6.01%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-1.02百万美元，每股收益-0.24美元，毛利-15000.00美元，市盈率-0.04倍。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2430727717?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-26 21:32","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2430727717","market":"us","top_or_hot":-1,"title":"Kintara Therapeutics, Inc.股价拉升20.44% 市值涨151.85万美元","media":"自选股智能写手","content":"<div>\n<p>北京时间2024年04月26日21时32分，Kintara Therapeutics, Inc.（KTRA.us）股票出现异动，股价大幅拉升20.44%。截至发稿，该股报0.190美元/股，成交量2672.4万股，换手率68.46%，振幅6.01%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-1.02百万美元，每股收益-0.24美元，毛利-15000.00美元，市盈率-0.04倍。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621323987b3f235&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kintara Therapeutics, Inc.股价拉升20.44% 市值涨151.85万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKintara Therapeutics, Inc.股价拉升20.44% 市值涨151.85万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-26 21:32 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621323987b3f235&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2024年04月26日21时32分，Kintara Therapeutics, Inc.（KTRA.us）股票出现异动，股价大幅拉升20.44%。截至发稿，该股报0.190美元/股，成交量2672.4万股，换手率68.46%，振幅6.01%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-1.02百万美元，每股收益-0.24美元，毛利-15000.00美元，市盈率-0.04倍。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621323987b3f235&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KTRA","symbol_name":"Kintara Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621323987b3f235&s=b","article_id":"2430727717","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042621323987b3f235&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2430727717","pubTimestamp":1714138359,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2024年04月26日21时32分，Kintara Therapeutics, Inc.股票出现异动，股价大幅拉升20.44%。Kintara Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，Biodexa Pharmaceuticals Plc、Cassava Sciences Inc C/Wts 15/11/2024、Tevogen Bio Holdings Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Kintara Therapeutics, Inc.、Processa Pharmaceuticals, Inc.较为活跃，换手率分别为585.22%、68.61%、20.73%，振幅较大的相关个股有Cassava Sciences Inc C/Wts 15/11/2024、Biodexa Pharmaceuticals Plc、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为34.80%、31.73%、24.13%。Kintara Therapeutics, Inc.公司简介：Kintara Therapeutics Inc从事针对医疗需求未得到满足的患者的新型癌症疗法的开发。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KTRA":"Kintara Therapeutics, Inc.","LENZ":"Therapeutics","DMPWW":"Kintara Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Kintara Therapeutics, Inc. 's stock price rose 20.44%, and its market value rose by $1.5185 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DMPWW":1,"KTRA":1,"LENZ":1},"content_text":"北京时间2024年04月26日21时32分，Kintara Therapeutics, Inc.（KTRA.us）股票出现异动，股价大幅拉升20.44%。截至发稿，该股报0.190美元/股，成交量2672.4万股，换手率68.46%，振幅6.01%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-1.02百万美元，每股收益-0.24美元，毛利-15000.00美元，市盈率-0.04倍。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。Kintara Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，Biodexa Pharmaceuticals Plc、Cassava Sciences Inc C/Wts 15/11/2024(To Pur Com)、Tevogen Bio Holdings Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Kintara Therapeutics, Inc.、Processa Pharmaceuticals, Inc.较为活跃，换手率分别为585.22%、68.61%、20.73%，振幅较大的相关个股有Cassava Sciences Inc C/Wts 15/11/2024(To Pur Com)、Biodexa Pharmaceuticals Plc、Psyence Biomedical Ltd C/Wts 25/01/2029(To Pur Com)，振幅分别为34.80%、31.73%、24.13%。Kintara Therapeutics, Inc.公司简介：Kintara Therapeutics Inc从事针对医疗需求未得到满足的患者的新型癌症疗法的开发。 该公司正在开发两种晚期、3 期就绪的疗法，通过降低风险的开发项目来满足明确的未满足的医疗需求。 这两个项目是用于 GBM 的 VAL-083 和用于 CMBC 的 REM-001。VAL-083是一种具有新颖作用机制的小分子化疗药物，已证明对一系列癌症具有临床活性，包括中枢神经系统、卵巢和其他实体瘤。 该公司通过单一的业务部门进行癌症适应症的研究和开发，并主要在一个地理区域内开展业务，即北美。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}